Infliximab biosimilar is under clinical development by Xentria and currently in Phase II for Pulmonary Sarcoidosis. According to GlobalData, Phase II drugs for Pulmonary Sarcoidosis does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Infliximab biosimilar LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Infliximab biosimilar overview
Infliximab biosimilar (XTMAB-16) is under development for the treatment of pulmonary sarcoidosis. The drug candidate is a human recombinant monoclonal antibody. It is administered through intravenous route. It acts by targeting TNF alpha.
Xentria overview
Xentria is a biopharmaceutical company that focuses on developing drugs to address medical needs through patient engagement and new scientific strategies, fostering sustainable growth and treating disease burdens. The company is headquartered in Chicago, Illinois, the US.
For a complete picture of Infliximab biosimilar’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
